Virtu Financial LLC Sells 14,915 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Virtu Financial LLC reduced its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 39.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 22,986 shares of the company’s stock after selling 14,915 shares during the period. Virtu Financial LLC’s holdings in Aquestive Therapeutics were worth $114,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in Aquestive Therapeutics by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock valued at $8,306,000 after acquiring an additional 90,543 shares during the period. State Street Corp increased its stake in shares of Aquestive Therapeutics by 52.1% in the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after purchasing an additional 512,682 shares in the last quarter. Blue Owl Capital Holdings LP raised its position in shares of Aquestive Therapeutics by 30.3% in the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after purchasing an additional 265,000 shares during the period. Janney Montgomery Scott LLC lifted its stake in shares of Aquestive Therapeutics by 4.9% during the 3rd quarter. Janney Montgomery Scott LLC now owns 923,285 shares of the company’s stock valued at $4,598,000 after buying an additional 42,800 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Aquestive Therapeutics in the 2nd quarter worth approximately $594,000. Institutional investors own 32.45% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on AQST shares. Leerink Partners boosted their target price on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Wednesday, November 6th. Cantor Fitzgerald began coverage on Aquestive Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $17.00 target price for the company. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Aquestive Therapeutics has a consensus rating of “Buy” and an average price target of $11.00.

Aquestive Therapeutics Stock Up 5.2 %

Aquestive Therapeutics stock opened at $3.64 on Friday. The stock has a market cap of $331.89 million, a price-to-earnings ratio of -8.09 and a beta of 2.62. The business has a 50-day simple moving average of $4.74 and a 200 day simple moving average of $4.06. Aquestive Therapeutics, Inc. has a 52 week low of $1.84 and a 52 week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same period in the previous year, the firm posted ($0.03) EPS. On average, research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.47 earnings per share for the current year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.